Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic

dc.creatorFerreira, Paulo Michel Pinheiro
dc.creatorSousa, Rayran Walter Ramos de
dc.creatorDittz, Dalton
dc.creatorSousa, João Marcelo de Castro e
dc.creatorLeal, Francisco Leonardo Torres
dc.creatorBezerra, Daniel Pereira
dc.date2023-06-05T14:37:12Z
dc.date2023-06-05T14:37:12Z
dc.date2023
dc.date.accessioned2023-09-26T21:49:05Z
dc.date.available2023-09-26T21:49:05Z
dc.identifierFERREIRA, Paulo Michel Pinheiro et al. Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. Brazilian Journal of Pharmaceutical Sciences, v. 59, p. 1-27, 2023.
dc.identifier2175-9790
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/58926
dc.identifier10.1590/s2175-97902023e21067
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8873698
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
dc.descriptionWe critically analyzed clinical trials performed with chloroquine (CQ) and hydroxychloroquine (HCQ) with or without macrolides during the first wave of COVID-19 and discussed the design and limitations of peer-reviewed studies from January to July 2020. Seventeen studies were eligible for the discussion. CQ and HCQ did not demonstrate clinical advantages that justified their inclusion in therapeutic regimens of free prescription for treatment or prophylactic purposes, as suggested by health authorities, including in Brazil, during the first wave. Around August 2020, robust data had already indicated that pharmacological effects of CQ, HCQ and macrolides as anti-SARS-CoV-2 molecules were limited to in vitro conditions and largely based on retrospective trials with low quality and weak internal validity, which made evidence superficial for decision-making. Up to that point, most randomized and nonrandomized clinical trials did not reveal beneficial effects of CQ or HCQ with or without macrolides to reduce lethality, rate of intubation, days of hospitalization, respiratory support/mechanical ventilation requirements, duration, type and number of symptoms, and death and were unsuccessful in increasing virus elimination and/or days alive in hospitalized or ambulatory patients with COVID-19. In addition, many studies have demonstrated that side effects are more common in CQ-or HCQ-treated patients.
dc.formatapplication/pdf
dc.languageeng
dc.publisheruniversidade de São Paulo
dc.rightsopen access
dc.subjectAminoquinolinas
dc.subjectCoronavírus
dc.subjectComorbidade
dc.subjectEfeito adverso
dc.subjectHospitalização
dc.subjectAminoquinolines
dc.subjectCoronavirus
dc.subjectComorbidity
dc.subjectAdverse effect
dc.subjectHospitalization
dc.subjectAminoquinolinas
dc.subjectCoronavírus
dc.subjectComorbidade
dc.subjectHospitalização
dc.titleAntimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic
dc.typeArticle


Este ítem pertenece a la siguiente institución